期刊文献+

参芪扶正注射液联合CAF方案化疗对乳腺癌患者造血功能、免疫功能和生活质量的影响 被引量:14

Effects of Shenqi Fuzheng Injection Combined with CAF Regimen on Hematopoietic Function,Immune Function and Quality of Life in Patients with Breast Cancer
下载PDF
导出
摘要 目的:探讨参芪扶正注射液联合CAF方案化疗对乳腺癌患者造血功能、免疫功能和生活质量的影响。方法:选择2叭2年1月-2017年1月在医院进行治疗的乳腺癌者128例,按照随机数字的方法分为对照组和观察组,每组64例患者,对照组患者采用cAF的化疗方案,观察组患者在对照组化疗方案的基础上使用参芪扶正注射液,对治疗的效果进行对比。结果:两组患者的造血功能和免疫功能指标均出现了不同程度的恶化,但是观察组患者恶化的程度低于对照组患者,各类指标的数据差异具有统计学意义(P〈0.05)。观察组患者的治疗效果,治疗有效率,疾病控制率,生活质量改善程度均优于对照组,数据差异具有统计学意义(P〈0.05)。结论:利用参芪扶正注射液联合CAF方案对乳腺癌患者进行干预,可以缓解患者造血功能的衰退和免疫功能的破坏,使患者的生活质量得到改善,值得在临床范围内进行推广。 Objective:To investigate the effect of Shenqi Fuzheng Injection combined with CAF regimen on hematopoi- etic function, immune function and quality of life in patients with breast cancer. Methods: A total of 128 cases of breast cancer treated in our hospital from January 2012 to January 2017 were divided into control group and observation group according to the random number method. Each group had 64 patients. Patients in the control group were treated with CAF chemotherapy, and the observation group was treated with Shenqi Fuzheng Injection on the basis of the chemotherapy regi- men of the control group, and the therapeutic effect was compared. Results : The hematopoietic function and immune func- tion indexes of the two groups showed different degrees of deterioration, but the degree of deterioration in the observation group was lower than that in the control group, and the data of the indexes was statistically significant(P 〈 0.05 ). The improvement rate of treatment, treatment efficiency, disease control rate and quality of life of the observation group were better than those of the control group, and the difference was statistically significant(P 〈0.05). Conclusion: The use of Shenqi Fuzheng Injection combined with CAF program can relieve hematopoietic function in patients with recession and immune function damage when intervening patients with breast cancer and so the quality of life of patients is improved. It is worth to promote in clinic.
作者 张志东 彭文 陈吉柏 ZHANG Zhidong;PENG Wen;CHEN Jibai(Department of Cardiothoracic Surgery,Danzhou People's Hospital,Danzhou 571700,Hainan,China)
出处 《中华中医药学刊》 CAS 北大核心 2018年第8期1904-1908,共5页 Chinese Archives of Traditional Chinese Medicine
基金 海南省自然科学基金项目(20168294)
关键词 化疗 乳腺癌 免疫功能 chemotherapy breast cancer immune function
  • 相关文献

参考文献9

二级参考文献74

  • 1王书梅,郭彦伟,黄国胜.参芪扶正注射液在乳腺癌术后辅助化疗中的应用[J].中国医药导报,2006,3(17). 被引量:3
  • 2中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:268
  • 3王雅杰.肿瘤分子靶向治疗进展[J].实用肿瘤杂志,2006,21(3):209-212. 被引量:8
  • 4徐兵河.蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4):241-244. 被引量:85
  • 5Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics[J].CA Cancer J Clin,2005,55:74-108.
  • 6Schiller JH,Harrington D.Comparison of four chemotherapy regi-mens for advanced non-small cell lung cancer[J].N Engl JMed,2002,346:92-98.
  • 7Endo M,Yamamoto N,Sakai H,et al.Phase II study of 3-weeklyS-1 plus cisplatin in patients with advanced non-small-cell lungcancer,S-1 cooperative study group[J].Ann Oncol 2006,17:ix224(abstract 752).
  • 8Tamura K,Okamoto I,Ozaki T,et al.Phase I/II study of a S-1plus carboplatin(CBDCA)in patients with advanced non-smallcell lung cancer(NSCLC)[J].Ann Oncol 2008,19:vii108(abstract 292).
  • 9Nokihara H,Nagai S,Kato T,et al.Phase II study of S-1 in non-small cell lung cancer(NSCLC)patients previously treated with aplatinum-based regimen[J].Thorac Oncol 2007,2:s687(ab-stract P2-290).
  • 10Satouchi M,Kotani Y,Katakami N,et al.Randomized phase IIstudy of two different schedules of gemcitabine and oral S-1 inchemo-naive patients with advanced non-small cell lung cancer[J].J Clin Oncol 2008,26:449s.

共引文献121

同被引文献201

引证文献14

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部